Aliases:This biomarker is also known as:
- secretory leukocyte peptidase inhibitor,
- secretory leukocyte protease inhibitor (antileukoproteinase),
- Mucus proteinase inhibitor,
- WAP four-disulfide core domain protein 4,
- Seminal proteinase inhibitor,
SLPI is a secreted inhibitor which protects epithelial tissues from serine proteases. It is found in various secretions including seminal plasma, cervical mucus, and bronchial secretions, and has affinity for trypsin, leukocyte elastase, and cathepsin G. Its inhibitory effect contributes to the immune response by protecting epithelial surfaces from attack by endogenous proteolytic enzymes; the protein is also thought to have broad-spectrum anti-biotic activity.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
Levels of the four proteins (SLPI, TFPI, TFPI2, and TIMP1) were studied in a set of 12 late stage lung cancer serum samples and 12 normal serum samples using the immunoaffinity-MRM methodology. It was found that the immunoaffinity-mass spectrometry-based quantification approach provides a specific and accurate assay for verifying the expression of potential biomarkers in patient serum samples especially for those proteins for which the necessary reagents for ELISA development are unavailable. (From PMID:18388126)
Researchers have developed an immunoaffinity-mass spectrometry-based approach using antibodies to enrich multiple proteins of interest from sera followed by LC-MRM-based quantification. As a proof of concept, it was demonstrated that CEA can be detected and quantified in a subset of patient sera. This is the first reported detection of CEA in sera using a mass spectrometry-based approach in serum samples. This method has allowed quantifying potential protein biomarkers in sera in the low ng/ml range with an acceptable CV. This approach was further applied to potential protein biomarkers discovered from tumor cell lines and tumor tissues. A linear response was obtained from a multiplex spiking experiment in normal human sera for secretory leukocyte peptidase inhibitor (4-500 ng/ml), tissue factor pathway inhibitor (TFPI) (42-1000 ng/ml), tissue factor pathway inhibitor 2 (TFPI2) (2-250 ng/ml), and metalloproteinase inhibitor 1 (TIMP1) (430-1000 ng/ml). (From PMID:18388126)
Overexpression of SLPI has been measured in invasive and low malignant potential tumors compared with benign and normal tissues.
Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. SLPI alone was not a strong predictor.
|QA State:||Under Review|
- HGNC entry for SLPI from Genenames
- KEGG entry for SLPI from Genome.jp
- Entrez entry for SLPI all NCBI Databasese
- Human GEO Profiles for SLPI from NCBI GEO Profiles
- Human Geo Datasets containing term SLPI from NCBI GEO Datasets
- GWAS Study Datasets containing gene SLPI from GWAS
- Human Single Nucleotide Polymorphisms info for SLPI
- Human Gene(s) with 'SLPI' as Gene Name/Alias
- Human Gene RefSeq for SLPI from NCBI
- UniProtKB/Swiss-Prot entry for SLPI from Uniprot
- Human Protein RefSeq for SLPI from NCBI
- FDA web page describing approval of SLPI
No other associated resources found.
|UniProt Accession #:||P03973|
|Mutated Sites Count:||23|
|Associated Pubmed ID Count||5|
|Affected Protein Function Sites Count:||4|